1. Home
  2. ORLA vs ACAD Comparison

ORLA vs ACAD Comparison

Compare ORLA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orla Mining Ltd.

ORLA

Orla Mining Ltd.

HOLD

Current Price

$13.39

Market Cap

4.5B

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$21.66

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORLA
ACAD
Founded
2007
1993
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
3.8B
IPO Year
2016
2000

Fundamental Metrics

Financial Performance
Metric
ORLA
ACAD
Price
$13.39
$21.66
Analyst Decision
Strong Buy
Buy
Analyst Count
2
22
Target Price
$21.00
$30.55
AVG Volume (30 Days)
3.1M
1.6M
Earning Date
05-08-2026
05-06-2026
Dividend Yield
0.12%
N/A
EPS Growth
N/A
69.12
EPS
N/A
0.02
Revenue
N/A
$726,437,000.00
Revenue This Year
$63.44
$18.80
Revenue Next Year
N/A
$11.70
P/E Ratio
$107.37
$1,083.25
Revenue Growth
N/A
40.45
52 Week Low
$9.16
$19.69
52 Week High
$21.98
$28.35

Technical Indicators

Market Signals
Indicator
ORLA
ACAD
Relative Strength Index (RSI) 47.05 50.28
Support Level $12.53 $21.12
Resistance Level $14.14 $22.03
Average True Range (ATR) 0.76 0.65
MACD 0.02 0.02
Stochastic Oscillator 42.27 61.45

Price Performance

Historical Comparison
ORLA
ACAD

About ORLA Orla Mining Ltd.

Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects: the Camino Rojo gold and silver project in Zacatecas State, the Musselwhite gold mine project located in Ontario and the South Railroad projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: